Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

OLE data FORTIFY risankizumab role in Crohn’s disease
13 Dec 2024
bởiAudrey Abella
Data from the ongoing open-label long-term extension (OLE) of the phase III FORTIFY trial presented at AIBD 2024 support the role of risankizumab for the treatment of moderate-to-severe active Crohn’s disease (CD).
13 Dec 2024

Generic antiobesity drugs viable after successful weight loss with GLP-1 RA
12 Dec 2024
bởiStephen Padilla
Older-generation generic antiobesity medications (AOMs) for weight maintenance may be prescribed to patients who have achieved successful weight loss with glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, suggests a study.
12 Dec 2024







